

**Table 2.** Subgroup of individuals with biopsy-proven NAFLD with available serum cytokine measurements (n=310).

<b>Cytokines (pg/ml)*</b>	<b>Fibrosis stages 0-1 (N = 220)</b>	<b>Fibrosis stages <math>\geq</math>2 (N = 90)</b>	<b>P value</b>
CTACK	776.84 (649.01-929.66)	850.31 (701.80-1056.10)	0.022
Eotaxin	75.59 (52.39-90.54)	77.77 (55.73-107.22)	0.064
FGF basic	33.86 (29.12-48.58)	43.06 (32.94-47.24)	0.843
G-CSF	138.08 (81.89-202.93)	160.97 (130.43-226.89)	0.006
GM-CSF	4.12 (2.14-7.59)	5.27 (4.00-7.35)	0.087
GRO- $\alpha$	416.98 (341.84-472.43)	432.33 (394.51-464.83)	0.005
HGF	529.92 (436.29-680.82)	628.36 (540.22-818.19)	<0.001
IFN- $\alpha$ 2	8.49 (5.01-13.59)	12.17 (6.92-14.88)	0.007
IFN- $\gamma$	22.24 (12.87-36.72)	39.99 (25.85-50.65)	<0.001
IL-1 $\alpha$	11.14 (5.02-17.89)	29.89 (16.56-31.85)	<0.001
IL-1 $\beta$	3.43 (1.81-6.64)	4.49 (2.98-6.50)	0.037
IL-1RA	360.03 (272.17-492.22)	433.56 (299.24-686.91)	0.003
IL-2	4.67 (2.23-10.17)	24.05 (5.46-27.91)	<0.001
IL-2R $\alpha$	61.94 (50.91-92.75)	63.65 (55.76-78.85)	0.019
IL-3	1.59 (1.25-1.83)	1.59 (1.32-1.72)	0.595
IL-4	1.68 (1.27-2.37)	2.06 (1.50-2.31)	0.097
IL-5	73.18 (21.85-94.46)	70.70 (57.98-81.49)	0.132
IL-6	4.22 (2.41-11.46)	5.16 (4.02-6.51)	<0.001
IL-7	12.97 (8.80-18.63)	19.10 (9.73-24.54)	<0.001
IL-8	26.45 (14.40-44.95)	22.69 (15.67-45.52)	0.904
IL-9	99.16 (84.66-118.78)	128.85 (99.28-151.80)	<0.001
IL-10	5.00 (1.89-14.29)	18.44 (9.17-23.59)	<0.001
IL-12(P70)	4.78 (2.62-6.94)	11.63 (4.62-14.25)	<0.001
IL-12(P40)	70.99 (42.69-111.78)	250.26 (80.76-292.59)	<0.001
IL-13	7.34 (3.95-15.75)	7.07 (4.71-11.87)	0.109
IL-15	301.08 (195.96-756.52)	294.00 (224.97-337.97)	<0.001
IL-16	119.54 (84.09-164.82)	104.04 (70.38-181.63)	0.499
IL-17	6.95 (4.44-10.03)	17.53 (5.28-20.06)	<0.001
IL-18	66.46 (49.24-86.70)	77.22 (61.97-98.86)	0.004
IP-10	864.05 (597.97-1268.26)	1168.49 (785.99-1781.83)	<0.001
LIF	34.78 (11.52-79.13)	91.22 (16.85-107.59)	0.002
MCP-1	57.81 (41.16-73.28)	70.22 (49.28-84.66)	0.004
MCP-3	3.29 (1.24-4.69)	3.57 (2.50-4.64)	0.41
M-CSF	14.07 (10.13-25.13)	18.14 (13.10-24.58)	0.006
MIF	1745.01 (1222.01-2463.51)	1921.51 (1319.59-2928.79)	0.011

MIG	310.82 (226.26-423.69)	443.52 (342.70-708.98)	<0.001
MIP-1 $\alpha$	5.86 (3.37-10.14)	5.19 (3.08-8.69)	0.245
MIP-1 $\beta$	100.16 (86.80-128.98)	103.62 (85.72-128.71)	0.49
$\beta$ -NGF	1.49 (0.98-2.82)	3.88 (1.77-5.07)	<0.001
PDGF-BB	5375.71 (4208.44-6949.90)	5590.47 (4078.97-7840.46)	0.111
RANTES	14131.56 (10304.62-19667.00)	16147.92 (11436.02-21262.74)	0.023
SCF	69.00 (56.92-86.75)	71.36 (56.56-92.13)	0.587
SCGF- $\beta$	129356.20 (112701.56-150094.53)	150635.51 (130341.73-175613.90)	<0.001
SDF-1 $\alpha$	601.95 (510.56-721.52)	639.10 (518.16-783.95)	0.135
TNF- $\alpha$	45.67 (35.99-61.28)	56.58 (48.85-66.57)	<0.001
TNF- $\beta$	96.12 (82.95-113.59)	106.16 (95.31-115.55)	0.005
TRAIL	34.70 (28.13-45.34)	35.55 (26.77-43.80)	0.671
VEGF-A	219.95 (167.50-310.69)	203.46 (164.40-256.03)	0.239

\* 310 individuals with NAFLD (220 patients with fibrosis stages 0-1 and 90 patients with fibrosis stages  $\geq 2$ ) had measured a total of 48 serum cytokines using the Bio-plex 200 system and matched kits.

*Abbreviations:* IFN, Interferon; IL, interleukin; LIF, leukemia inhibitory factor; MIP, macrophage inflammatory protein; TNF, tumor necrosis factor; TRAIL, TNF related apoptosis inducing ligand; VEGF-A, vascular endothelial growth factor-A.